Discovery of regulatory T cells programmed to suppress an immune response
US10596195B2 · kind B2 · utility
3Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 13, 2017 |
| Grant date | Mar 24, 2020 |
| Priority date | — |
| Expiry date | Jan 13, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/1114
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.